https://smallcaps.com.au/article/imugene-approval-phase-1-clinical-trial-new-cancer-immunotherapy-pd1-vaxx
Imugene obtains two-pronged approval for Phase 1 clinical trial of new cancer immunotherapy PD1-Vaxx
Jul 17, 2020 - Immuno-oncology company Imugene (ASX: IMU) received a timely regulatory boost courtesy of a second Human Research Ethics Committee (HREC) approval to commence...
https://medicalresearch.com/imugene-building-pipeline-b-cell-peptide-cancer-vaccines/imugene/
MedicalResearch.com | imugene
medicalresearchimugene
https://imugene.com/technology/b-cell-immunotherapies/
B-Cell Immunotherapies - Imugene Limited
B-cell immunotherapies link an immunogenic protein with a B-cell epitope and incorporate an adjuvant to produce a B-cell cancer vaccine that induces the body...
bcellimugenelimited
https://stockwirex.com/asx-stock-news/biotech-health/imu-imugene-rd-tax-refund-february-2026/
IMU Imugene Receives $2.7M R&D Refund - Feb 2026
r dimureceivesrefundfeb
https://imugene.com/investors/asx-announcements/
ASX Announcements - Imugene Limited
asx announcementsimugenelimited